Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab

Authors: Katherine Cotangco DO1, Mary Meram DO2, and M. Patrick Lowe MD3
View More View Less
  • 1 Department of Obstetrics and Gynecology, University of Illinois;
  • | 2 Department of Obstetrics and Gynecology, Amita Health Hospital; and
  • | 3 Gynecologic Cancer Institute, Chicago, Illinois.
Restricted access

The estimated 5-year survival rate for patients with stage IV uterine leiomyosarcoma is 29%, with a median survival of <1 year. This report describes a patient with stage IVB leiomyosarcoma who experienced stable disease for 15 months on pembrolizumab. A woman aged 62 years, gravida 2 para 2, with postmenopausal bleeding and a necrotic uterine fibroid underwent a dilation and curettage and was diagnosed with uterine leiomyosarcoma. CT imaging showed pulmonary and bony metastasis. She underwent surgical staging with biopsy-proved stage IVB disease. A mixed partial response was noted using first- and second-line chemotherapy. Molecular tumor profiling confirmed PD-L1 expression. The patient was started on pembrolizumab, and at the time of writing she is status post 23 cycles with stable disease. Pembrolizumab was well tolerated and aided prolonged disease stabilization.

Submitted November 6, 2019; accepted for publication March 19, 2020.

Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Katherine Cotangco, DO, Department of Obstetrics and Gynecology, University of Illinois, 1801 West Taylor Street, Suite 1E, Chicago, IL 60612. Email: krcotangco@gmail.com
  • 1.

    Tawbi HA, Burgess M, Bolejack V, et al. . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18:14931501.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol 2018;151:562572.

  • 3.

    Hensley ML, Barrette BA, Baumann K, et al. . Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer 2014;24(Suppl 3):S6166.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Abu-Rustum NR, Yashar CM, Bean S, et al. . NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 1.2020. Accessed June 30, 2020. To view the most recent version, visit NCCN.org

  • 5.

    Hensley ML, Blessing JA, Degeest K, et al. . Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008;109:323328.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Hensley ML, Blessing JA, Mannel R, et al. . Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008;109:329334.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hyman DM, Grisham RN, Hensley ML. Management of advanced uterine leiomyosarcoma. Curr Opin Oncol 2014;26:422427.

  • 8.

    Lee HY, Shin SJ, Kim HS, et al. . Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. Cancer Res Treat 2012;44:4349.

  • 9.

    Stewart J. Keytruda approval history. Accessed March 25, 2020. Available at: https://www.drugs.com/history/keytruda.html

  • 10.

    George S, Miao D, Demetri GD, et al. . Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 2017;46:197204.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Ott PA, Bang YJ, Berton-Rigaud D, et al. . Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017;35:25352541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2239 1624 107
PDF Downloads 620 515 92
EPUB Downloads 0 0 0